Evogene (NASDAQ:EVGN) Research Coverage Started at StockNews.com

Investment analysts at StockNews.com initiated coverage on shares of Evogene (NASDAQ:EVGN) in a report issued on Friday. The brokerage set a “sell” rating on the biotechnology company’s stock.

Evogene Price Performance

EVGN stock opened at $0.70 on Friday. Evogene has a twelve month low of $0.45 and a twelve month high of $1.44. The company has a market cap of $28.86 million, a P/E ratio of -1.32 and a beta of 1.47. The business has a fifty day moving average of $0.76 and a 200-day moving average of $0.75.

Evogene (NASDAQ:EVGN) last announced its quarterly earnings data on Thursday, March 7th. The biotechnology company reported ($0.13) earnings per share for the quarter, topping the consensus estimate of ($0.14) by $0.01. Evogene had a negative return on equity of 76.93% and a negative net margin of 423.39%. The firm had revenue of $0.58 million during the quarter, compared to analysts’ expectations of $1.73 million. During the same period in the previous year, the business posted ($0.07) EPS.

Institutional Trading of Evogene

An institutional investor recently raised its position in Evogene stock. Silverarc Capital Management LLC increased its stake in shares of Evogene Ltd. (NASDAQ:EVGN) by 3,000.0% in the third quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 3,100,000 shares of the biotechnology company’s stock after purchasing an additional 3,000,000 shares during the period. Silverarc Capital Management LLC owned approximately 7.52% of Evogene worth $1,818,000 as of its most recent SEC filing. Hedge funds and other institutional investors own 10.40% of the company’s stock.

About Evogene

Evogene Ltd., together with its subsidiaries, operates as a computational biology company. It focuses on product discovery and development in life-science based industries, including human health and agriculture, through the use of its Computational Predictive Biology (CPB) platform. The company operates through three segments: Agriculture, Human Health, and Industrial Applications.